Multifaceted anti-amyloidogenic and pro-amyloidogenic effects of C-reactive protein and serum amyloid P component in vitro

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Ozawa, Daisaku ^a   Nomura, Ryo ^a   Mangione, P Patrizia ^b   Hasegawa, Kazuhiro ^a   Okoshi, Tadakazu ^a   Porcari, Riccardo ^b   Bellotti, Vittorio ^b   Naiki, Hironobu ^a  

^a UNIVERSITY OF FUKUI   (Japan)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; CALCIUM; GLUTATHIONE TRANSFERASE; SERUM AMYLOID P;

ALZHEIMER DISEASE; AMYLOIDOSIS; BLOOD; GENETICS; HUMAN; INNATE IMMUNITY; METABOLISM; MISSENSE MUTATION; PATHOLOGY; PROTEIN FOLDING; PROTEINOSIS;

ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PEPTIDES; AMYLOIDOSIS; BETA 2-MICROGLOBULIN; C-REACTIVE PROTEIN; CALCIUM; GLUTATHIONE TRANSFERASE; HUMANS; IMMUNITY, INNATE; MUTATION, MISSENSE; PROTEIN AGGREGATION, PATHOLOGICAL; PROTEIN FOLDING; SERUM AMYLOID P-COMPONENT;

EID: 84977262514     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep29077     Document Type: Article

References (56)

1. Du Clos, T. W. Pentraxins: structure, function, and role in inflammation. ISRN Inflamm. 2013, 379040(2013).
2. Pepys, M. B. et al. Amyloid P component. A critical review. Amyloid 4, 274-295 (1997).
3. Pepys, M. B. & Hirschfield, G. M. C-reactive protein: a critical update. J. Clin. Invest. 111, 1805-1812 (2003).
4. Pepys, M. B. et al. Comparative clinical study of protein SAP (amyloid P component) and C-reactive protein in serum. Clin. Exp. Immunol. 32, 119-124 (1978).
5. Johnson, P. T. et al. Individuals homozygous for the age-related macular degeneration risk-conferring variant of complement factor H have elevated levels of CRP in the choroid. Proc. Natl. Acad. Sci. USA 103, 17456-17461 (2006).
6. Kushner, I. & Kaplan, M. H. Studies of acute phase protein. I. An immunohistochemical method for the localization of Cx-reactive protein in rabbits. Association with necrosis in local inflammatory lesions. J. Exp. Med. 114, 961-974 (1961).
7. Thiele, J. R. et al. Dissociation of pentameric to monomeric C-reactive protein localizes and aggravates inflammation: in vivo proof of a powerful proinflammatory mechanism and a new anti-inflammatory strategy. Circulation 130, 35-50 (2014).
8. Hammond, D. J. Jr. et al. Identification of acidic pH-dependent ligands of pentameric C-reactive protein. J. Biol. Chem. 285, 36235-36244 (2010).
9. Singh, S. K. et al. Exposing a hidden functional site of C-reactive protein by site-directed mutagenesis. J. Biol. Chem. 287, 3550-3558 (2012).
10. Gebert, G., Benzing, H. & Strohm, M. Changes in the interstitial pH of dog myocardium in response to local ischemia, hypoxia, hyper-and hypocapnia, measured continuously by means of glass microelectrodes. Pflügers Arch. 329, 72-81 (1971).
11. Öörni, K. et al. Acidification of the intimal fluid: the perfect storm for atherogenesis. J. Lipid. Res. 56, 203-214 (2015).
12. Rajamäki, K. et al. Extracellular acidosis is a novel danger signal alerting innate immunity via the NLRP3 inflammasome. J. Biol. Chem. 288, 13410-13419 (2013).
13. Duong, T., Nikolaeva, M. & Acton, P. J. C-reactive protein-like immunoreactivity in the neurofibrillary tangles of Alzheimer's disease. Brain Res. 749, 152-156 (1997).
14. Iwamoto, N., Nishiyama, E., Ohwada, J. & Arai, H. Demonstration of CRP immunoreactivity in brains of Alzheimer's disease: immunohistochemical study using formic acid pretreatment of tissue sections. Neurosci. Lett. 177, 23-26 (1994).
15. McGeer, E. G., Yasojima, K., Schwab, C. & McGeer, P. L. The pentraxins: possible role in Alzheimer's disease and other innate inflammatory diseases. Neurobiol. Aging 22, 843-848 (2001).
16. Botto, M. et al. Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene. Nat. Med. 3, 855-859 (1997).
17. Mold, M., Shrive, A. K. & Exley, C. Serum amyloid P component accelerates the formation and enhances the stability of amyloid fibrils in a physiologically significant under-saturated solution of amyloid-β 42. J. Alzheimers Dis. 29, 875-881 (2012).
18. Myers, S. L. et al. A systematic study of the effect of physiological factors on β 2-microglobulin amyloid formation at neutral pH. Biochemistry 45, 2311-2321 (2006).
19. Tennent, G. A., Lovat, L. B. & Pepys, M. B. Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc. Natl. Acad. Sci. USA 92, 4299-4303 (1995).
20. Togashi, S. et al. Serum amyloid P component enhances induction of murine amyloidosis. Lab. Invest. 77, 525-531 (1997).
21. Hutchinson, W. L., Hohenester, E. & Pepys, M. B. Human serum amyloid P component is a single uncomplexed pentamer in whole serum. Mol. Med. 6, 482-493 (2000).
22. Janciauskiene, S., García de Frutos, P., Carlemalm, E., Dahlbäck, B. & Eriksson, S. Inhibition of Alzheimer β-peptide fibril formation by serum amyloid P component. J. Biol. Chem. 270, 26041-26044 (1995).
23. Andersson, K., Pokrzywa, M., Dacklin, I. & Lundgren, E. Inhibition of TTR aggregation-induced cell death. A new role for serum amyloid P component. PLoS One 8, e55766 (2013).
24. Coker, A. R., Purvis, A., Baker, D., Pepys, M. B. & Wood, S. P. Molecular chaperone properties of serum amyloid P component. FEBS Lett. 473, 199-202 (2000).
25. Dabbs, R. A., Wyatt, A. R., Yerbury, J. J., Ecroyd, H. & Wilson, M. R. Extracellular chaperones. Top Curr. Chem. 328, 241-268 (2013).
26. Wyatt, A. R., Yerbury, J. J., Dabbs, R. A. & Wilson, M. R. Roles of extracellular chaperones in amyloidosis. J. Mol. Biol. 421, 499-516. (2012).
27. Wyatt, A. R., Yerbury, J. J., Ecroyd, H. & Wilson, M. R. Extracellular chaperones and proteostasis. Annu. Rev. Biochem. 82, 295-322 (2013).
28. Ozawa, D. et al. Inhibition of β 2-microglobulin amyloid fibril formation by α 2-macroglobulin. J. Biol. Chem. 286, 9668-9676 (2011).
29. Valleix, S. et al. Hereditary systemic amyloidosis due to Asp76Asn variant β 2-microglobulin. N. Engl. J. Med. 366, 2276-2283 (2012).
30. Coker, A. R. et al. The crystal structure of the calcium-free Serum Amyloid P-component decamer. The Proceedings of the XIIIth International Symposium on Amyloidosis "From Misfolded Proteins to Well-Designed Treatment" [Hazenberg, B. P. & Bijzet, J. (ed.)] [64-66] (Groningen, The Netherlands, 2013).
31. Baltz, M. L., De Beer, F. C., Feinstein, A. & Pepys, M. B. Calcium-dependent aggregation of human serum amyloid P component. Biochim. Biophys. Acta 701, 229-236 (1982).
32. Ashton, A. W., Boehm, M. K., Gallimore, J. R., Pepys, M. B. & Perkins, S. J. Pentameric and decameric structures in solution of serum amyloid P component by X-ray and neutron scattering and molecular modelling analyses. J. Mol. Biol. 272, 408-422 (1997).
33. Isaacs, A. M., Senn, D. B., Yuan, M., Shine, J. P. & Yankner, B. A. Acceleration of amyloid β-peptide aggregation by physiological concentrations of calcium. J. Biol. Chem. 281, 27916-27923 (2006).
34. Brännström, K., Ohman, A., Lindhagen-Persson, M. & Olofsson, A. Ca2+ enhances Aβ polymerization rate and fibrillar stability in a dynamic manner. Biochem. J. 450, 189-197 (2013).
35. Fournier, T., Medjoubi-N, N. & Porquet, D. Alpha-1-acid glycoprotein. Biochim. Biophys. Acta 1482, 157-171 (2000).
36. Zsila, F. Chaperone-like activity of the acute-phase component human serum alpha 1-acid glycoprotein: inhibition of thermal-and chemical-induced aggregation of various proteins. Bioorg. Med. Chem. Lett. 20, 1205-1209 (2010).
37. Yerbury, J. J. et al. The extracellular chaperone clusterin influences amyloid formation and toxicity by interacting with prefibrillar structures. FASEB J. 21, 2312-2322 (2007).
38. Yerbury, J. J., Kumita, J. R., Meehan, S., Dobson, C. M. & Wilson, M. R. α2-Macroglobulin and haptoglobin suppress amyloid formation by interacting with prefibrillar protein species. J. Biol. Chem. 284, 4246-4254 (2009).
39. Yoshimura, Y. et al. Distinguishing crystal-like amyloid fibrils and glass-like amorphous aggregates from their kinetics of formation. Proc. Natl. Acad. Sci. USA 109, 14446-14451 (2012).
40. Kumita, J. R. et al. The extracellular chaperone clusterin potently inhibits human lysozyme amyloid formation by interacting with prefibrillar species. J. Mol. Biol. 369, 157-167 (2007).
41. Narayan, P. et al. The extracellular chaperone clusterin sequesters oligomeric forms of the amyloid-β (1-40) peptide. Nat. Struct. Mol. Biol. 19, 79-83 (2011).
42. Wyatt, A. R. et al. Hypochlorite-induced structural modifications enhance the chaperone activity of human α 2-macroglobulin. Proc. Natl. Acad. Sci. USA 111, E2081-E2090 (2014).
43. Mettenburg, J. M., Webb, D. J. & Gonias, S. L. Distinct binding sites in the structure of α 2-macroglobulin mediate the interaction with β-amyloid peptide and growth factors. J. Biol. Chem. 277, 13338-13345 (2002).
44. Carver, J. A., Rekas, A., Thorn, D. C. & Wilson, M. R. Small heat-shock proteins and clusterin: intra-and extracellular molecular chaperones with a common mechanism of action and function? IUBMB Life 55, 661-668 (2003).
45. Niwa, T., Kanamori, T., Ueda, T. & Taguchi, H. Global analysis of chaperone effects using a reconstituted cell-free translation system. Proc. Natl. Acad. Sci. USA 109, 8937-8942 (2012).
46. Stull, F., Koldewey, P., Humes, J. R., Radford, S. E. & Bardwell, J. C. Substrate protein folds while it is bound to the ATP-independent chaperone Spy. Nat. Struct. Mol. Biol. 23, 53-58 (2016).
47. DeMattos, R. B. et al. Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 99, 10843-10848 (2002).
48. Bell, R. D. et al. Transport pathways for clearance of human Alzheimer's amyloid β-peptide and apolipoproteins E and J in the mouse central nervous system. J. Cereb. Blood Flow Metab. 27, 909-918 (2007).
49. Heneka, M. T., Golenbock, D. T. & Latz, E. Innate immunity in Alzheimer's disease. Nat. Immunol. 16, 229-236 (2015).
50. Masters, S. L. & O'Neill, L. A. Disease-associated amyloid and misfolded protein aggregates activate the inflammasome. Trends Mol. Med. 17, 276-282 (2011).
51. Seong, S. Y. & Matzinger, P. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat. Rev. Immunol. 4, 469-478 (2004).
52. Pepys, M. B. et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 417, 254-259 (2002).
53. Carlucci, F., Cook, H. T., Garg, A., Pepys, M. B. & Botto, M. Lack of effect of a single injection of human C-reactive protein on murine lupus or nephrotoxic nephritis. Arthritis Rheum 62, 245-249 (2010).
54. Hawkins, P. N., Tennent, G. A., Woo, P. & Pepys, M. B. Studies in vivo and in vitro of serum amyloid P component in normals and in a patient with AA amyloidosis. Clin. Exp. Immunol. 84, 308-316 (1991).
55. Pontet, M., Engler, R. & Jayle, M. F. One step preparation of both human C-reactive protein and CIt. FEBS Lett. 88, 172-175 (1978).
56. Chiba, T. et al. Amyloid fibril formation in the context of full-length protein: effects of proline mutations on the amyloid fibril formation of β 2-microglobulin. J. Biol. Chem. 278, 47016-47024 (2003).